Policy | September 15, 2021
Jharkhand to set up pharma park
The pharma park will be built at an estimated cost of Rs 34.94 crore and will be spread over 50 acres at Chanho close to Ranchi
The pharma park will be built at an estimated cost of Rs 34.94 crore and will be spread over 50 acres at Chanho close to Ranchi
The order strengthens the company’s position in the East African market
_256_384.jpg)
In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, Cabozantinib has shown better PFS (Progression-Free Survival).
The division will focus on products that are required during ophthalmic surgical procedures like cataracts and refractive surgeries among others
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The company said Revital NXT is India’s first nutrition bar with the goodness of natural ginseng, 16 vitamins & minerals and triple blend protein
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The company has been sold to Shinshin Pharmaceuticals
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
Subscribe To Our Newsletter & Stay Updated
